Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262512 | 1.00 | ADORA2A (0.52) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL7262510 | 1.00 | ADORA2A (0.52) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL16198307 | 0.88 | FLT4 (0.43) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL28948370 | 0.87 | P2RY1 (0.44) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL9193608 | 0.87 | EGFR (0.43) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26230942 | 0.86 | P2RY1 (0.47) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL20008181 | 0.86 | ADORA2A (0.58) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL26230945 | 0.86 | P2RY1 (0.47) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL28948317 | 0.85 | CYP3A4 (0.46) | PDE4APDE4BPDE4CPDE4DRAB9A | |
| SCHEMBL28948290 | 0.85 | FLT4 (0.45) | ADORA2AADORA1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462935-B1 | Process for the preparation of tenofovir | LAURUS LABS PRIVATE LTD (IN) | 2015-01-21 | — | — | EP | disclosed |
| US-8791259-B2 | Process for the preparation of Tenofovir | LAURUS LABS PRIVATE LIMITED (IN) | 2014-07-29 | — | — | US | disclosed |
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012081032-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-06-21 | — | — | WO | disclosed |
| EP-2462935-A1 | Process for the preparation of tenofovir | Laurus Labs Private Limited (IN) | 2012-06-13 | — | — | EP | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-6653296-B1 | 2-phosphonomethoxypropyl derivatives of purine and pyrimidine bases | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-11-25 | — | — | US | disclosed |
| US-6479673-B1 | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2002-11-12 | — | — | US | disclosed |
| EP-0654037-B1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1999-05-12 | — | — | EP | disclosed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | SAMHD1, TYMP, DCTPP1 | ADORA2A 2915/4885ADORA1 1096/4885PDE4A 333/4885 |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | DCTD, SAMHD1, SLC28A1 | ADORA2A 1618/4885ADORA1 1617/4885PDE4A 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.